Philippe Rougier

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.5K citations

Medicine, Oncology, Pharmacotherapy +13

<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre et al. · Cancer Research · 2006 · 2.2K citations

Medicine, Oncology, Pharmacology +17

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius et al. · The Lancet · 2008 · 1.9K citations · Full text

Medicine, Oncology, Surgery +17